Canada markets closed

Arcturus Therapeutics Holdings Inc. (ARCT)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
33.13-3.18 (-8.76%)
At close: 04:00PM EDT
33.00 -0.13 (-0.39%)
After hours: 06:55PM EDT
Full screen
Trade prices are not sourced from all markets
Previous Close36.31
Open36.08
Bid38.08 x 1200
Ask38.17 x 1800
Day's Range33.02 - 36.96
52 Week Range14.62 - 43.81
Volume579,247
Avg. Volume413,386
Market Cap891.701M
Beta (5Y Monthly)2.64
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Business Wire

    Arcturus Therapeutics Announces Fourth Quarter and Fiscal Year 2023 Financial Update and Pipeline Progress

    SAN DIEGO, March 07, 2024--Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a global messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases, today announced its financial results for the fourth quarter ended December 31, 2023, and provided corporate updates.

  • Business Wire

    Arcturus Therapeutics to Present at the Barclays 26th Annual Global Healthcare Conference

    SAN DIEGO, February 26, 2024--Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a global late-stage clinical messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases, today announced that the Company will present at a Fireside Chat hosted by Barclays 26th Annual Global Healthcare Conference in Miami, on Thursday, March 14, 2024, at 11:45 a.m. Eastern Time.

  • Business Wire

    Arcturus Therapeutics Receives Orphan Medicinal Product Designation from the European Commission (EC), for ARCT-032, for the Treatment of Cystic Fibrosis

    SAN DIEGO, February 22, 2024--Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a global late-stage clinical messenger RNA medicines company focused on the development of infectious disease vaccines and medicines to treat unmet medical needs within liver and respiratory rare diseases, today announced that the European Commission (EC), based on a positive opinion issued by the European Medicines Agency (EMA), has granted orphan medicinal product designation for the Co